Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of January 2021. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not provide consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It exclusively details specific share acquisition transactions.
| Transaction Date | Instrument | Price per ADS | Volume (ADSs) | Exchange |
|---|---|---|---|---|
| 2021-01-19 | American Depositary Shares (ADSs) | $38.5819 | 83.896 | New York Stock Exchange (XNYS) |
| 2021-01-19 | American Depositary Shares (ADSs) | $38.5819 | 1,119.805 | New York Stock Exchange (XNYS) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document reports two separate acquisitions of ADSs by company executives following the re-investment of dividends paid to shareholders on January 14, 2021.
Management Commentary and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. The transactions were executed automatically via a dividend reinvestment plan.
Key Facts for Investor Verification
- Transaction Nature: Both transactions were acquisitions of ADSs resulting from the re-investment of dividends, not open market purchases or sales.
- Executives Involved:
- Mr. J Ford (SVP & General Counsel): Acquired 83.896 ADSs.
- Mr. B McNamara (CEO, GSK Consumer Healthcare): Acquired 1,119.805 ADSs.
- Transaction Price: Both transactions occurred at a price of $38.5819 per ADS on January 19, 2021.
- Dividend Date: The underlying dividends were paid on January 14, 2021.